TheJakartaPost
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Agence France-Presse
Vials of the drug Remdesivir lie during a press conference about the start of a study with the Ebola drug Remdesivir in particularly severely ill patients at the University Hospital Eppendorf (UKE) in Hamburg, northern Germany on April 8, 2020, amidst the new coronavirus COVID-19 pandemic.The European Commission has ordered 30,000 treatment doses of the antiviral medication remdesivir from US drugs giant Gilead, it announced Wednesday. (AFP/Ulrich Perrey)
The European Commission has ordered 30,000 treatment doses of the antiviral medication remdesivir from US drugs giant Gilead, it announced Wednesday.
Sold under the brand name Veklury, remdesivir is the first medicine to be approved by the EU to treat victims of the COVID-19 pandemic in EU member states and Britain.
It is hoped the drug will shorten recovery times for patients with severe infections and it will be made available early next month.
The first batch of doses will cost 63 million euros ($73 million) and ought to cover needs for the next few months before a second procurement contract in October.
